diabetic macular oedema (dMo) is a leading cause of vision loss in the working-age population worldwide. Numerous early studies suggest an important role for intravitreal anti-VEGF agents such as bevacizumab in the management of dMo. We reviewed manuscripts that had investigated pharmacokinetic, efficacy, safety, dose and frequency of intravitreal bevacizumab (iVB) injections as well as effect of macular ischaemia, initial macular thickness and optical coherence tomography (ocT) patterns of dMo on the final results of treatment with iVB. in summery literature searches disclosed that almost all studies published up to now provided evidence supporting use of iVB for treatment of either naïve or persistent dMo in short and long term up to 2 years.
of type 2 patients not requiring insulin. 1 laser photocoagulation was the only evidence based treatment available for subjects with clinical significant macular oedema, defined by the early treatment diabetic retinopathy study (ETdRS). 2 however the beneficial effect of macular laser photocoagulation (MPc) on dMo was inferred only because it reduce the risk of moderate visual loss by 50 %. 2 For diffuse dMo, MPc has even more limited results, and based on a study, performing modified MPc visual acuity (Va) was increased in only 14.5 % of the eyes. 3 Moreover, diabetic retinopathy clinical research network (dRcR. Net) has recently shown a Va improvement of more than five letters in 51, 47 and 62 % of cases by MPc at 1, 2 and 3 years of follow-up respectively. [4] [5] [6] destructive nature, adverse effects and suboptimal efficacy of MPc have led to investigators to find alternative treatments. Pharmacotherapy of dMo with intravitreal drugs especially anti-VEGFs such as ranibizumab, bevacizumab and aflibercept have been the focus of the most recent attentions, among them bevacizumab has greatest popularity because of higher availability and lower cost. The off-label use of bevacizumab has been applied to many neovascular diseases of the eye such as age-related macular degeneration, proliferative diabetic retinopathy and other retinovascular disorders such as macular oedema secondary to retinal vein occlusion and diabetic retinopathy. [7] [8] The use of intravitreal bevacizumab (iVB) is becoming increasingly more prevalent, however some unresolved issues such as ideal regimen, duration of treatment, combination therapy and long-term safety are unanswered and deserve further investigations. in this review article we have tried to provide some answers for common questions in this regard based on published literature.
Pathophysiology of Diabetic Macular Oedema
Several physiological mechanisms have been proposed to contribute to the pathogenesis of dMo. The exact mechanisms by which elevated glucose initiates the vascular disruption and results in the ultimate blood retinal barrier (BRB) breakdown in diabetic retinopathy remain poorly defined. There are several hypotheses that contribute to dMo formation including:
1. increase in hydrostatic pressure that was described by Starling.
Similar to congestive heart failure, dMo can be considered as a congestive macular oedema. Based on Starling law hydrostatic and oncotic pressure counteract each other; pressure differences are responsible for the movement of fluid between tissue beds and intravascular spaces. changes in vessel diameter together with increased hydrostatic pressure can contribute to oedema formation. Furthermore the above mentioned mechanism can increase in shear stress which may cause damage to endothelial cells and cause endothelial decoupling over time. [9] [10] [11] 2. ischaemia secondary to hypoxia can lead to decrease in oxygen tension in retina which results in vasodilation of the retinal vessels that can increase macular oedema by increasing hydrostatic pressure. increased in oxygen tension may decrease macular oedema by reversing the earlier described mechanism.
3. hyperglycaemia per se or together with other mechanisms may induce endothelial dysfunction and cause more vascular damage. and 38 days after injection that was somehow similar to ranibizumab. where it diffuses in the vitreous, rather than entering through the choroidal blood flow. One study investigated changes of serum VEGF concentration after iVB injection in treatment of DMO and reported maximal reduction of serum VEGF was noted on the 7th post-injection day and 28 days later again VEGF level in serum was raised. 38 One experimental study found that concentration of bevacizumab in the vitreous of the rabbits' fellow eye varied incrementally, from 0.35 ng/ml at 1 day to 11.7 ng/ml at 4 weeks while concentration of bevacizumab in the vitreous of injected eye was 400 µg/ml at day 1 and 10 µg/ml at day 30. 
Published Results of Bevacizumab for Diabetic Macular Oedema
Bevacizumab is still an off-label treatment for DMO. published randomised clinical trials for efficacy of intravitreal bevacizumab for treatment of DMO can be categorised in to two major groups:
1. intravitreal bevacizumab for treatment of naïve DMO; and 2. intravitreal bevacizumab for refractory DMO (see Table 1 ).
Intravitreal Bevacizumab for Treatment of Naïve Diabetic Macular Oedema
the results of one randomised clinical trial has been published in three separate reports (publications are related to the same study) and disclosed that in terms of Va improvement the significant superiority of the iVB over the combined iVB/iVt and Mpc treatment that had been observed at month 6 did not sustain up to 24 months. the authors concluded that although iVB treatment may be a better choice than iVB/iVt and Mpc in short term, the magnitude of beneficial effect of iVB diminished over time. in that study iVB yielded a better visual outcome at 6 months compared with Mpc however a change in cMt beyond the 6-week time point that corresponded to the vision change was not detected. interestingly no adjunctive effect of iVt could be demonstrated in short and long term. and Mpc had no short-term benefit in the Drcr network study. 42 One other clinical trial reported that iVB was an effective drug for treatment of DMO however adding iVt did not affect the outcomes measures except for elevating the intraocular pressure (iOp). 43 another study reported that Va and cMt at 12 months were comparable in eyes that were treated with iVB, iVB/iVt and iVt and no beneficial effect of the combination injection was detected. versus the Mpc group (-118 µm) but it was not statistically significant. 46 Several other case series studies have also provided evidence supporting beneficial effect of iVB for persistent DMO with the logic that persistence or recurrence of DMO after Mpc may be attributed to the production of VEGF by the residual ischaemic retina, which may result in persistent or recurrent DMO despite Mpc. [47] [48] [49] in summary, literature searches conducted in this study disclosed that almost all studies published up to now provided evidence supporting use of iVB for treatment of either naïve or persistent DMO in short and long term up to 2 years. 115 eyes a) three injection of 1.25 mg iVB at 6 weeks intervals B) iVt (2 mg) followed by two injections of iVB at 6 weeks intervals c) sham injection cMt was reduced significantly in both the iVB and iVB/ iVt groups. Significant improvement of BcVa was seen in both the iVB and iVB/ iVt groups. no significant differences were detected in the changes of cMt and BcVa between the iVB and iVB / iVt groups. 
BCVA = best corrected visual acuity; CMT = central macular thickness; DMO = diabetic macular oedema; IVB = intravitreal bevacizumab; IVT = intravitreal triamcinolone; MPC = macular photocoagulation.

Safety of Bevacizumab
Initial Macular Thickness, Patterns of Diabetic Macular Oedema and Response to Bevacizumab
the introduction of oct allowed for objective morphometric evaluation of Dmo. in addition oct produces cross-sectional images of the retina that have been found to correlate well with retinal histology as demonstrated by light microscopy.
Four patterns of structural changes in Dmo have been defined; sponge-like retinal swelling, cystoid macular oedema (cmE), serous retinal detachment (SrD) and tractional retinal detachment (trD). [55] [56] [57] initial cmt is an important factor in decision making for treatment of Dmo. it has been shown that foveal thickening more than 180 µm by oct may be the earliest detectable sign of macular thickening and it may be an indicator for a closer follow up of patients with diabetes. 58 one study has found that a retinal thickening in Dmo of 60 % above the normal value has a 50 % probability for reversal of thickening with mpc, whereas thickening of more than 130 % has a less than 2.5 % probability. 59 one study demonstrated that in cases of Dmo with cmt of more than 300 µm had the worst response to mpc. 60 in another recently published report it was demonstrated that in short term (up to 6 weeks) eyes with various initial cmt showed a better Va improvement to iVB than mpc. this better response to iVB persisted only in the eyes with initial cmt of ≥350 µm up to 36 weeks. 61 one study evaluated the effect of different treatment modalities on morphological variants of Dmo and they reported that only beneficial effect of mpc was on sponge like Dmo. 62 Some studies reported that the effectiveness of iVB on diffuse Dmo was dependent on the oct pattern; it was more effective on sponge like pattern rather than those associated with cmE and SrD. 63, 64 it is important to note that visual acuity changes are not always parallel to cmt changes in eyes with Dmo. Factors such as duration, extent and severity of macular oedema, presence of foveal hard exudate as well as macular ischaemia could have confounding effect.
Prophylactic Intravitreal Bevacizumab for Diabetic Macular Oedema in Association with Cataract surgery
progression of Dmo and formation of cmE are common complications after cataract surgery in the presence of diabetic retinopathy. [65] [66] [67] the pathogenesis of these complications may be related to the changes and rise in the concentration of VEGF in response to surgical trauma and inflammation. 29 one study investigated cmE following cataract surgery in patients with diabetic retinopathy and they reported that 6 % of the controls and 12 % of diabetic eyes developed a clinical cmE up to 6
weeks. in this report increased frequency of macular changes with both Fa and oct was reported. however changes on oct or Fa were often seen without obvious effect on Va. in this study the final visual outcome in eyes with mild to moderate retinopathy, without previous macular oedema was reported to be as good as in normal eyes at 6 months. they reported that one month after surgery their control group (not receiving iVB) showed a significant increase in cmt, whereas the bevacizumab group did not show any change. however after 6 months no significant differences in cmt and post-operative visual acuity between two groups could be detected. phacoemulsification seems to be logical even in the absence of large supportive studies.
Bevacizumab Dosage and Frequency of Injections for Diabetic Macular Oedema
One of the unresolved issues in using iVB for treatment of DMO is its optimal dosage and frequency of injections. Some studies suggested use of higher dosage of iVB to achieve a better visual and anatomical outcomes but studies that compared the efficacy of 1.25 mg with 2.5 mg iVB for DMO have shown that no significant difference in terms of BcVa and Oct was observed between iVB at doses of 1.25 mg or 2.5 mg. 71, 72 the frequency of iVB injections for DMO is another controversial subject. the effectiveness of intravitreal bevacizumab injection has been reported to last 6, 8 and 12 weeks. [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] in the Drcr network and BOlt study, a pre-scheduled repeated iVB injections were performed at baseline, 6 and 12 week time point. Subsequent injections were guided by an Oct-based re-treatment protocol. [42] [43] [44] [45] [46] in the another study a baseline iVB injection performed and re-treated injections performed on an as-needed bases rather than a pre-scheduled injections. for pegaptanib, to less than uS$50 per dose for bevacizumab. that is why the use of bevacizumab is becoming increasingly more prevalent. 76, 77 Future studies should evaluate the role of combined intravitreal bevacizumab with non-steroidal anti-inflammatory drugs (nSaiDs) as well as supplemental inspired oxygen to treat hypoxia for the treatment of DMO. 78, 80 Furthermore researches need to investigate new molecular targets to prevent or delay the progression of DMO and develop novel strategies for sustained intraocular delivery of anti-VEGF agents to reduce the burden, cost and risk of injections.
Description of Evidence
literature search last were conducted in December 2012 in pubMed with no date restriction and limited to studies published in English.
the search strategy used the terms 'diabetic macular edema', 'bevacizumab', 'avastin', 'safety of intravitreal bevacizumab', 'pattern of diabetic macular edema', 'macular ischemia' and 'dose and frequency of intravitreal bevacizumab'. n
